Skip to main content
. 2018 Feb 7;24(5):623–630. doi: 10.3748/wjg.v24.i5.623

Table 4.

Risk factors at or after the initial Crohn’s disease surgery associated with time to the second Crohn’s disease surgery

Main effects HR 95%CI P value FDR
Immunomodulators1 0.486 0.306-0.773 0.002 0.026
GM-CSF Ab level 3.493 1.430-8.538 0.005 0.030
GM-CSF cytokine level 2.489 1.292-4.796 0.005 0.030
B2 disease behavior2 1.415 0.517-3.874 0.491 0.624
B3 disease behavior3 0.415 0.146-1.176 0.091 0.145
Smoking4 1.286 0.277-5.981 0.743 0.800
ASCA IgG, U/mL 1.318 0.799-2.174 0.270 0.378
Age at diagnosis 0.983 0.963-1.003 0.094 0.145
Clostridium difficile infection 0.035 0.001-1.092 0.051 0.113
antiTNF-α5 1.272 0.662-2.447 0.461 0.615
ATG16L1 polymorphism 1.793 0.982-3.273 0.052 0.113
IRGM polymorphism 0.092 0.004-2.262 0.136 0.201
ASCA IgA, U/mL 0.976 0.755-1.262 0.852 0.852
NOD2 polymorphisms 1.123 0.741-1.702 0.577 0.673
Interactions
GM-CSF Ab level and smoking 0.612 0.454-0.825 0.001 0.026
GM-CSF cytokine level and ATG16L1 0.652 0.480-0.885 0.005 0.030
GM-CSF Ab level and ASCA IgG, U/mL 0.808 0.674-0.968 0.018 0.081
GM-CSF Ab level and ATG16L1 0.719 0.538-0.962 0.023 0.081
B2 disease behavior and Clostridium difficile 21.57 1.456-319.271 0.023 0.081
B2 disease behavior and smoking 1.601 0.318-8.059 0.560 0.673
B3 disease behavior and smoking 5.117 0.966-27.141 0.050 0.113
GM-CSF Ab level and Clostridium difficile 2.865 1.065-7.715 0.033 0.104
GM-CSF cytokine level and Clostridium difficile 0.902 0.325-2.501 0.840 0.852
Smoking and IRGM 0.406 0.145-1.134 0.079 0.145
ASCA IgG, U/mL and IRGM 1.867 0.908-3.835 0.083 0.145
GMCSF cytokine level and antiTNF-α 0.765 0.562-1.041 0.082 0.145
GM-CSF Ab level and antiTNF-α 0.941 0.703-1.260 0.676 0.757
GM-CSF cytokine level and ASCA IgA, U/mL 0.865 0.750-0.997 0.041 0.113
1

Use of Immunomodulators between first and second CD surgery including: Azathioprine, 6-Mercaptopurine, Methotrexate;

2

Stricturing behavior (B2) compared to Inflammatory (B1) disease behavior;

3

Penetrating behavior (B3) compared to Inflammatory (B1) disease behavior;

4

Active smoker before the first CD surgery;

5

Use of Anti-tumor Necrosis Factor-alpha therapy between first and second CD surgery including: Infliximab, Adalimumab. Cox proportional hazard model; A Cox proportional hazard model was fitted with main effects and first-order interactions of clinical and genotype variables. A stepwise variable selection was performed to select the relevant subset of variables. Within the model, P value was adjusted with the cutoff at FDR < 0.05. Model fitting and selection were generated using R 3.1.1 (http://cran.r-project.org). Table 4 displays the P-values for all fitted terms in the final model. GM-CSF Ab: Granulocyte-macrophage colony-stimulating factor auto-antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies; CD: Crohn’s disease.